Roughly 20 million of those people have moderate-to-severe forms of the disease, but 85% of cases go undiagnosed, the company told CNBC earlier this year
Key Takeaways The global market for GLP-1 drugs could reach $190 billion by 2035, more than double 2025 levels
Eder, K., Felgner, J., Becker, K., & Kluge, H
And in late 2025, the dominoes started falling
Over the last couple of decades, Pratley says, the scientific research community has learned that incretin hormones, including GLP-1, GIP, and others, are important regulators of metabolism with impacts on glycemia, lipids, and body weight
The practical limitation is its short half-life requiring daily dosing and producing a relatively modest GH pulse compared to the CJC-1295/ipamorelin combination